Citations

Clear

168 citation(s) found for "Perlmutter, J".

Practical guidance for telemedicine use in neuro-oncology
Dunbar, Erin, Gan, Hui , Kurz, Sylvia C. , Mandel, Jacob , Mohile, Nimish, Nevel, Kathryn , Taylor, Jennie , Ullrich, Nicole J. , Welch, Mary , Wasilewski, Andrea , Mrugala, Maciej , Kurz, Sylvia , Strowd, Roy E. , Jordan, Justin T.

Mayo Clinic

Neuro-Oncology Practice | January 17, 2022 | Volume: 9 | Issue: 2 | Pages: 91-104

10.1093/nop/npac002 | PMID 35371525 Get It

AbstractWhile the COVID-19 pandemic has catalyzed the expansion of telemedicine into nearly every specialty of medicine, few articles have summarized current practices and recommendations for integrating virtual care in the practice of neuro-oncology. This article identifies current telemedicine practice, provides practical guidance for conducting telemedicine visits, and generates recommendations for integrating virtual care into neuro-oncology practice. Practical aspects of telemedicine are summarized including when to use and not use telemedicine, how to conduct a virtual visit, who to include in the virtual encounter, unique aspects of telehealth in neuro-oncology, and emerging innovations.
Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study
Archambault, Alexi , Jeon, Jihyoun , Thomas, Minta , Harrison, Tabitha A. , Bishop, D. Timothy , Brenner, Hermann , Casey, Graham , Chan, Andrew T. , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gunter, Marc J. , Hoffmeister, Michael , Li, Li , Pai, Rish K. , Parfrey, Patrick S. , Rennert, Gad , Lee, Jeffrey K. , Slattery, Martha L. , Win, Aung Ko , Woods, Michael O. , Peterse, Elisabeth F.P. , Cao, Yin , Du, Mengmeng , Corley, Douglas A. , Peters, Ulrike , Song, Mingyang , Archambault, Alexi N , Harrison, Tabitha A , Bishop, D Timothy , Brenner, Hermann , Chan, Andrew T , Chang-Claude, Jenny , Figueiredo, Jane C , Gruber, Stephen B , Gunter, Marc J , Guo, Feng , Hoffmeister, Michael , Jenkins, Mark A , Marchand, Loïc Le , Moreno, Victor , Pai, R K , Rennert, Gad , Sakoda, Lori C , Song, Mingyang , Win, Aung K , Woods, Michael O , Murphy, Neil , Campbell, Peter T , Peterse, Elisabeth F P , Cao, Yin , Liang, Peter S , Hayes, Richard B , Jeon, Jihyoun , Lin, Yi , Jenkins, Mark A. , Keku, Temitope O , Marchand, Loı̈c Le , Moreno, Vı́ctor , Newcomb, Polly A. , Sakoda, Lori C. , Song, Mingyang , Murphy, Neil , Campbell, Peter T. , Su, Yu-Ru , Lansdorp‐Vogelaar, Iris , Zeleniuch‐Jacquotte, Anne , Liang, Peter S. , Hsu, Li , Hayes, Richard B.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djac003 | PMID 35026030 Get It

AbstractBackgroundThe incidence of colorectal cancer (CRC) among individuals aged younger than 50 years has been increasing. As screening guidelines lower the recommended age of screening initiation, concerns including the burden on screening capacity and costs have been recognized, suggesting that an individualized approach may be warranted. We developed risk prediction models for early-onset CRC that incorporate an environmental risk score (ERS), including 16 lifestyle and environmental factors, and a polygenic risk score (PRS) of 141 variants.MethodsRelying on risk score weights for ERS and PRS derived from studies of CRC at all ages, we evaluated risks for early-onset CRC in 3486 cases and 3890 controls aged younger than 50 years. Relative and absolute risks for early-onset CRC were assessed according to values of the ERS and PRS. The discriminatory performance of these scores was estimated using the covariate-adjusted area under the receiver operating characteristic curve.ResultsIncreasing values of ERS and PRS were associated with increasing relative risks for early-onset CRC (odds ratio per SD of ERS = 1.14, 95% confidence interval [CI] = 1.08 to 1.20; odds ratio per SD of PRS = 1.59, 95% CI = 1.51 to 1.68), both contributing to case-control discrimination (area under the curve = 0.631, 95% CI = 0.615 to 0.647). Based on absolute risks, we can expect 26 excess cases per 10 000 men and 21 per 10 000 women among those scoring at the 90th percentile for both risk scores.ConclusionsPersonal risk scores have the potential to identify individuals at differential relative and absolute risk for early-onset CRC. Improved discrimination may aid in targeted CRC screening of younger, high-risk individuals, potentially improving outcomes.
Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes
Bustoros, Mark , Sklavenitis‐Pistofidis, Romanos , Boyle, Eileen M. , Neuse, Carl Jannes , Chavda, Selina J , Boehner, Cody J. , Rahmat, Mahshid , Zhitomirsky, Benny , Dutta, Ankit K. , Trippa, Lorenzo , Casneuf, Tineke, Boyle, Eileen M , Sklavenitis-Pistofidis, Romanos , Anand, Shankara K. , Redd, Robert , Tai, Yu‐Tzu , Dunford, Andrew , Stewart, Chip , Kastritis, Efstathios , Walker, Brian A. , Davies, Faith E. , Dimopoulos, Meletios Α. , Bergsagel, P. Leif , Yong, Kwee , Morgan, Gareth J. , Aguet, François , Getz, Gad , Ghobrial, Irene M.

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 723-723

10.1182/blood-2021-150767 Get It

Abstract Introduction: Multiple Myeloma (MM) is an incurable plasma cell malignancy commonly preceded by the asymptomatic stage smoldering multiple myeloma (SMM). MM is characterized with significant genomic heterogeneity of chromosomal gains and losses (CNVs), translocations, and point mutations (SNVs); alterations that are also observed in SMM patients. However, current SMM risk models rely solely on clinical markers and do not accurately capture progression risk. While incorporating some genomic biomarkers improves prediction, using all MM genomic features to comprehensively stratify patients may increase risk stratification precision in SMM. Methods: We obtained a total of 214 patient samples at SMM diagnosis. We performed whole-exome sequencing on 166 tumors; of these, RNA sequencing was performed on 100. Targeted capture was done on 48 additional tumors. Upon binarization of DNA features, we performed consensus non-negative matrix factorization to identify distinct molecular clusters. We then trained a random forest classifier on translocations, SNVs, and CNVs. The predicted clinical outcomes for the molecular subtypes were further validated in an independent SMM cohort of 74 patients. Results: We identified six genomic subtypes, four with hyperdiploidy (>48 chromosomes, HMC, HKR, HNT, HNF) and two with IgH translocations (FMD, CND) (Table 1). In multivariate analysis accounting for IMWG (20-2-20) clinical risk stages, high-risk (HMC, FMD, HKR) and intermediate-risk (HNT, HNF) genetic subtypes were independent predictors of progression (Hazards ratio [HR]: 3.8 and 5.5, P = 0.016 and 0.001, respectively). The low-risk, CND subtype harboring translocation (11;14) was enriched for the previously defined CD-2 MM signature defined by the B cell markers CD20 and CD79A (FDR = 0.003 ), showed upregulation of CCND1, E2F1, and E2F7 (FDR = 0.01, 0.0004, 0.08), and was enriched for G2M checkpoint, heme metabolism, and monocyte cell signature (FDR = 0.003, 0.003, 0.003, respectively). The FMD subtype with IgH translocations (4;14) and (14;16) was enriched for P53, mTORC1, unfolded protein signaling pathways and plasmacytoid dendritic cell signatures (FDR = 0.01, 0.005, 0.008, respectively). The HKR tumors were enriched for inflammatory cytokine signaling, MYC target genes, T regulatory cell signature, and the MM proliferative (PR) signatures (FDR = 0.02, 0.03, 0.007, 0.02, respectively). The APOBEC mutational signature was enriched in HMC and FMD tumors (P = 0.005), while there was no statistical difference across subtypes in the AID signature. The median follow-up for the primary cohort is 7.1 years. Median TTP for patients in HMC, FMD, and HKR was 3.8, 2.6, and 2.2 years, respectively; TTP for HNT and HNF was 4.3 and 5.2, respectively, while it was 11 years in CND patients (P = 0.007). Moreover, by analyzing the changes in MM clinical biomarkers over time, we found that patients from high-risk subgroups had higher odds of developing evolving hemoglobin and monoclonal protein levels over time (P = 0.01 and 0.002, respectively); Moreover, the absolute increase in M-protein was significantly higher in patients from the high-risk genetic subtypes at one, two, and five years from diagnosis (P = 0.001, 0.03, and 0,01, respectively). Applying the classifier to the external cohort replicated our findings where intermediate and high-risk genetic subgroups conferred increased risk of progression to MM in multivariate analysis after accounting for IMWG staging (HR: 5.5 and 9.8, P = 0.04 and 0.005, respectively). Interestingly, within the intermediate-risk clinical group in the primary cohort, patients in the high-risk genetic subgroups had increased risk of progression (HR: 5.2, 95% CI 1.5 - 17.3, P = 0.007). In the validation cohort, these patients also had an increased risk of progression to MM (HR: 6.7, 95% CI 1.2 - 38.3, P = 0.03), indicating that molecular classification improves the clinical risk-stratification models. Conclusion: We identified and validated in an independent dataset six SMM molecular subgroups with distinct DNA alterations, transcriptional profiles, dysregulated pathways, and risks of progression to active MM. Our results underscore the importance of molecular classification in addition to clinical evaluation in better identifying high-risk SMM patients. Moreover, these subgroups may be used to identify tumor vulnerabilities and target them with precision medicine efforts. Figure 1 Figure 1. Disclosures Bustoros: Janssen, Bristol Myers Squibb: Honoraria, Speakers Bureau; Takeda: Consultancy, Honoraria. Casneuf: Janssen: Current Employment. Kastritis: Amgen: Consultancy, Honoraria, Research Funding; Takeda: Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Consultancy, Honoraria, Research Funding. Walker: Bristol Myers Squibb: Research Funding; Sanofi: Speakers Bureau. Davies: Takeda: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Dimopoulos: Amgen: Honoraria; BMS: Honoraria; Takeda: Honoraria; Beigene: Honoraria; Janssen: Honoraria. Bergsagel: Genetech: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Patents & Royalties: human CRBN mouse; GSK: Consultancy, Honoraria; Celgene: Consultancy, Honoraria. Yong: BMS: Research Funding; Autolus: Research Funding; Takeda: Honoraria; Janssen: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; GSK: Honoraria; Amgen: Honoraria. Morgan: BMS: Membership on an entity's Board of Directors or advisory committees; Jansen: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees. Getz: IBM, Pharmacyclics: Research Funding; Scorpion Therapeutics: Consultancy, Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees. Ghobrial: AbbVie, Adaptive, Aptitude Health, BMS, Cellectar, Curio Science, Genetch, Janssen, Janssen Central American and Caribbean, Karyopharm, Medscape, Oncopeptides, Sanofi, Takeda, The Binding Site, GNS, GSK: Consultancy.
Digital symptom monitoring with patient-reported outcomes in community oncology practices: A U.S. national cluster randomized trial.
Basch, Ethan , Jansen, Jennifer , Henson, Sydney, Spears, Patricia A. , Jönsson, Mattias , Deal, Allison M. , Thanarajasingam, Gita , Cella, David , Kottschade, Lisa A. , Perlmutter, Jane , Strasser, Jon F., Zylla, Dylan M. , Basch, Ethan , Schrag, Deborah , Jansen, Jennifer , Stover, Angela M , Jonsson, Mattias , Deal, Allison , Bennett, Antonia V , Reeve, Bryce B. , Snyder, Claire , Bruner, Deborah Watkins , Miller, Robert S. , Strasser, Jon F., Zylla, Dylan , Dueck, Amylou C.

Mayo Clinic

Journal of Clinical Oncology | November 23, 2021 | Volume: 39 | Issue: 36_suppl | Pages: 349527-349527

10.1200/jco.2021.39.36_suppl.349527 Get It

349527 Background: Symptoms are common during cancer care but often go undetected. Digital systems that elicit patient-reported outcomes (PRO) surveys may detect symptoms early and prompt clinicians to intervene, thereby alleviating suffering and averting complications. Methods: In a cluster-randomized trial, U.S.-based community oncology practices were randomized 1:1 to digital symptom monitoring with PRO surveys, or to usual care control. Patients receiving systemic treatment for metastatic cancer were eligible. At PRO practices, participants were invited to complete a weekly survey via web or automated telephone system for up to one year, including questions about nine common symptoms, performance status, and falls. Severe or worsening symptoms triggered electronic alerts to care team nurses, and reports showing longitudinal symptom data were available to oncologists at visits. Pre-specified secondary outcomes included impact on physical function, symptom control, and health-related quality of life (HRQL). The primary outcome of survival is not yet mature. Results: At 52 practices, 1,191 patients were eligible and enrolled (593 PRO; 598 control). Clinically meaningful benefits were experienced in physical function by 13.8% more patients with PRO versus control (P=0.009); symptom control by 16.1% (P=0.003); and HRQL by 13.4% (P=0.006). Mean changes from baseline were superior with PRO versus control for physical function (mean difference 2.47, 95% CI 0.41-4.53; P=0.02), symptom control (2.56, 0.95-4.17; P=0.002), and HRQL (2.43, 0.90-3.96; P=0.002). Patients completed 20,565/22,486 (91.5%) of expected weekly PRO surveys. Conclusions: Digital symptom monitoring during cancer treatment confers clinical benefits. Clinical trial information: NCT03249090.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
Symmans, W. Fraser , Chen, Yunn-Yi, Klein, Molly, Nanda, Rita , Parker, Barbara A. , Datnow, Brian, Krings, Gregor , Wei, Shi , Duan, Xiuzhen, Chen, Beiyun, Sattar, Husain, Khazai, Laila , Zeck, Jay , Sams, Sharon B. , Mhawech‐Fauceglia, Paulette , Rendi, Mara H. , Sahoo, Sunati , Ocal, Idris Tolgay, Fan, Fang, LeBeau, Lauren, Vinh, Tuyethoa N., Troxell, Megan L. , Chien, A. Jo , Forero‐Torres, Andres , Ellis, Erin D. , Albain, Kathy S. , Liu, Minetta C. , Haley, Barbara , Clark, Amy S. , Kemmer, Kathleen, Lang, Julie E. , Edmiston, Kirsten K., Viscusi, Rebecca K., Northfelt, Donald W. , Khan, Qamar J. , Leyland‐Jones, Brian , Venters, Sara J., Shad, Sonal , Matthews, Jeffrey B. , Asare, Smita , Buxton, Meredith , Asare, Adam L. , Schwab, Richard B. , Veer, Laura van ‘t , Perlmutter, Jane , Yee, Douglas , Berry, Donald A. , Esserman, Laura J. , Symmans, W Fraser , Esserman, Laura J , Asare, Adam L , Yee, Douglas , Yau, Christina , Chen, Yunn‐Yi , Balassanian, Ronald , Pusztai, Lajos , Feldman, Michael D. , Wallace, Anne M. , Murthy, Rashmi Krishna , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Han, Hyo S , Matthews, Jeffrey B., Rugo, Hope S. , Helsten, Teresa L. , Hylton, Nola M. , Veer, Laura J. van’t , DeMichele, Angela

Mayo Clinic

JAMA Oncology | September 16, 2021 | Volume: 7 | Issue: 11 | Pages: 1654

10.1001/jamaoncol.2021.3690 | PMID 34529000 Get It

Revisiting FDA Approval of Aducanumab
Emerson, Scott S. , Ovbiagele, Bruce , Kryscio, Richard J. , Perlmutter, Joel S. , Kesselheim, Aaron S, Alexander, G. Caleb , Knopman, David S. , Ovbiagele, Bruce , Kesselheim, Aaron Seth

Mayo Clinic

New England Journal of Medicine | July 28, 2021 | Volume: 385 | Issue: 9 | Pages: 769-771

10.1056/nejmp2110468 | PMID 34320282 Get It

Predictive modeling of spread in adult‐onset isolated dystonia: Key properties and effect of tremor inclusion
Wang, Meng , Morgante, Francesca , Adler, Charles H. , Bäumer, Tobias , Berardelli, Alfredo , Blumin, Joel H. , Borsche, Max , Brashear, Allison , Deik, Andres , Duque, Kevin R. , Feuerstein, Jeanne , Fox, Susan H. , LeDoux, Mark S. , Leegwater‐Kim, Julie, Mahajan, Abhimanyu , Ondo, William G. , Pantelyat, Alexander , Pirio‐Richardson, Sarah, Roze, Emmanuel , Saunders‐Pullman, Rachel , Suchowersky, Oksana , Truong, Daniel , Morgante, Francesca , Adler, C H , Berardelli, Alfredo , Borsche, Max , Mahajan, Abhimanyu , Martino, Davide , Pantelyat, Alex , Sajobi, Tolulope T. , Berman, Brian D. , Espay, Alberto J. , Ferrazzano, Gina , Frank, Samuel , Hallett, Mark , Jankovic, Joseph J. , Malaty, Irene A. , Vidailhet, Marie , Shukla, Aparna Wagle , Perlmutter, Joel S. , Jinnah, H. A.

Mayo Clinic

European Journal of Neurology | July 22, 2021 | Volume: 28 | Issue: 12 | Pages: 3999-4009

10.1111/ene.15031 | PMID 34296504 Get It

AbstractBackground and purposeSeveral clinical and demographic factors relate to anatomic spread of adult‐onset isolated dystonia, but a predictive model is still lacking. The aims of this study were: (i) to develop and validate a predictive model of anatomic spread of adult‐onset isolated dystonia; and (ii) to evaluate whether presence of tremor associated with dystonia influences model predictions of spread.MethodsAdult‐onset isolated dystonia participants with focal onset from the Dystonia Coalition Natural History Project database were included. We developed two prediction models, one with dystonia as sole disease manifestation (“dystonia‐only”) and one accepting dystonia OR tremor in any body part as disease manifestations (“dystonia OR tremor”). Demographic and clinical predictors were selected based on previous evidence, clinical plausibility of association with spread, or both. We used logistic regressions and evaluated model discrimination and calibration. Internal validation was carried out based on bootstrapping.ResultsBoth predictive models showed an area under the curve of 0.65 (95% confidence intervals 0.62–0.70 and 0.62–0.69, respectively) and good calibration after internal validation. In both models, onset of dystonia in body regions other than the neck, older age, depression and history of neck trauma were predictors of spread.ConclusionsThis predictive modeling of spread in adult‐onset isolated dystonia based on accessible predictors (demographic and clinical) can be easily implemented to inform individuals’ risk of spread. Because tremor did not influence prediction of spread, our results support the argument that tremor is a part of the dystonia syndrome, and not an independent or coincidental disorder.
Non‐motor phenotypic subgroups in adult‐onset idiopathic, isolated, focal cervical dystonia
Wadon, Megan E. , Bailey, Grace , Yılmaz, Zehra, Hubbard, Emily , Alsaeed, Meshari , McLauchlan, Duncan , Barbano, Richard L. , Marsh, Laura , Fox, Susan H. , Rodriguez, Ramon L. , Comella, Cynthia , Reich, Stephen G. , Severt, William, Robinson, Amy, Factor, Stewart Alan , Adler, Charles H. , Goetz, Christopher G. , Perlmutter, Joel S. , Jinnah, H. A. , Harding, Katharine E , Sandor, Cynthia , Peall, Kathryn J.

Mayo Clinic

Brain and Behavior | July 21, 2021 | Volume: 11 | Issue: 8 | Pages: No page available

10.1002/brb3.2292 | PMID 34291595 Get It

Abstract Background : Non‐motor symptoms are well established phenotypic components of adult‐onset idiopathic, isolated, focal cervical dystonia (AOIFCD). However, improved understanding of their clinical heterogeneity is needed to better target therapeutic intervention. Here, we examine non‐motor phenotypic features to identify possible AOIFCD subgroups. Methods : Participants diagnosed with AOIFCD were recruited via specialist neurology clinics (dystonia wales: n = 114, dystonia coalition: n = 183). Non‐motor assessment included psychiatric symptoms, pain, sleep disturbance, and quality of life, assessed using self‐completed questionnaires or face‐to‐face assessment. Both cohorts were analyzed independently using Cluster, and Bayesian multiple mixed model phenotype analyses to investigate the relationship between non‐motor symptoms and determine evidence of phenotypic subgroups. Results : Independent cluster analysis of the two cohorts suggests two predominant phenotypic subgroups, one consisting of approximately a third of participants in both cohorts, experiencing increased levels of depression, anxiety, sleep impairment, and pain catastrophizing, as well as, decreased quality of life. The Bayesian approach reinforced this with the primary axis, which explained the majority of the variance, in each cohort being associated with psychiatric symptomology, and also sleep impairment and pain catastrophizing in the Dystonia Wales cohort. Conclusions : Non‐motor symptoms accompanying AOIFCD parse into two predominant phenotypic sub‐groups, with differences in psychiatric symptoms, pain catastrophizing, sleep quality, and quality of life. Improved understanding of these symptom groups will enable better targeted pathophysiological investigation and future therapeutic intervention.
Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
Knopman, David S. , Perlmutter, Joel S.

Mayo Clinic

Neurology | July 7, 2021 | Volume: 97 | Issue: 11 | Pages: 545-547

10.1212/wnl.0000000000012452 | PMID 34233938 Get It

Nongenetic Determinants of Risk for Early-Onset Colorectal Cancer
Archambault, Alexi , Jeon, Jihyoun , Harrison, Tabitha A. , Bishop, D. Timothy , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gunter, Marc J. , Hoffmeister, Michael , Li, Li , Pai, Rish K. , Parfrey, Patrick S. , Rennert, Gad , Sandler, Robert S. , Slattery, Martha L. , Song, Mingyang , Win, Aung Ko , Woods, Michael O. , Murphy, Neil , Zeleniuch‐Jacquotte, Anne , Liang, Peter S. , Du, Mengmeng , Peters, Ulrike , Hayes, Richard B. , Archambault, Alexi N , Jeon, Jihyoun , Harrison, Tabitha A , Bishop, D Timothy , Brenner, Hermann , Chang-Claude, Jenny , Figueiredo, Jane C , Gruber, Stephen B , Gunter, Marc J , Hoffmeister, Michael , Jenkins, Mark A , Moreno, Victor , Pai, R K , Rennert, Gad , Sakoda, Lori C , Song, Mingyang , Win, Aung K , Woods, Michael O , Campbell, Peter T , Liang, Peter S , Hayes, Richard B , Murphy, Neil , Sandler, Robert S , Zeleniuch-Jacquotte, Anne , Lin, Yi , Chan, Andrew T. , Jenkins, Mark A. , Keku, Temitope O , Marchand, Loı̈c Le , Moreno, Vı́ctor , Newcomb, Polly A. , Sakoda, Lori C. , Campbell, Peter T. , Su, Yu-Ru

Mayo Clinic

JNCI Cancer Spectrum | March 26, 2021 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/jncics/pkab029 | PMID 34041438 Get It

Abstract Background Incidence of early-onset (younger than 50 years of age) colorectal cancer (CRC) is increasing in many countries. Thus, elucidating the role of traditional CRC risk factors in early-onset CRC is a high priority. We sought to determine whether risk factors associated with late-onset CRC were also linked to early-onset CRC and whether association patterns differed by anatomic subsite. Methods Using data pooled from 13 population-based studies, we studied 3767 CRC cases and 4049 controls aged younger than 50 years and 23 437 CRC cases and 35 311 controls aged 50 years and older. Using multivariable and multinomial logistic regression, we estimated odds ratios (ORs) and 95% confidence intervals (CIs) to assess the association between risk factors and early-onset CRC and by anatomic subsite. Results Early-onset CRC was associated with not regularly using nonsteroidal anti-inflammatory drugs (OR = 1.43, 95% CI = 1.21 to 1.68), greater red meat intake (OR = 1.10, 95% CI = 1.04 to 1.16), lower educational attainment (OR = 1.10, 95% CI = 1.04 to 1.16), alcohol abstinence (OR = 1.23, 95% CI = 1.08 to 1.39), and heavier alcohol use (OR = 1.25, 95% CI = 1.04 to 1.50). No factors exhibited a greater excess in early-onset compared with late-onset CRC. Evaluating risks by anatomic subsite, we found that lower total fiber intake was linked more strongly to rectal (OR = 1.30, 95% CI = 1.14 to 1.48) than colon cancer (OR = 1.14, 95% CI = 1.02 to 1.27; P = .04). Conclusion In this large study, we identified several nongenetic risk factors associated with early-onset CRC, providing a basis for targeted identification of those most at risk, which is imperative in mitigating the rising burden of this disease.